Last reviewed · How we verify

Dabigatran Etexilate — Competitive Intelligence Brief

Dabigatran Etexilate (DABIGATRAN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Dabigatran Etexilate (DABIGATRAN) — Boehringer Ingelheim. Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dabigatran Etexilate TARGET DABIGATRAN Boehringer Ingelheim marketed 2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dabigatran Etexilate — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl48361. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: